For more information or to sign up for a trial
please contact our Clinical Trials Team:
(909) 478-7973
Trials by Tumor Types:
Breast Cancer Trials:
Breast - NCT05306340
A Phase 3, Open Label Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With Exemestane Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA)
OPEN TO ENROLLMENT
Breast – NCT05633654
A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05)
OPen to enrollment
Breast - NCT05501886
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
Open to enrollment
Breast – NCT04958785
A Phase 2 Study of Magrolimab Combination Therapy in Patients With Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer (ELEVATE TNBC)
Just-in-time Trial
Colon Cancer Trials:
Colon - NCT04793958
A randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with Colorectal Cancer with KRAS G12C mutation.
Closed to enrollment
Colon – NCT05546476
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study To Investigate The Efficacy, Safety and Tolerability of Ponsegromab in Patients with Cancer, Cachexia, and Elevated Concentrations of GDF-15, Followed By An Optional Open-Label Treatment Period
Closed to enrollment
Lung Cancer Trials:
Lung - NCT05353257
A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 or Placebo in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
OPEN TO ENROLLMENT
Lung - NCT05785767
A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50%
Open to entrollment
Lung - NCT05800015
A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody), Cemiplimab (Anti-PD-1 Antibody), and Chemotherapy Versus Cemiplimab and Chemotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Irrespective of PD-L1 Expression Levels
open to enrollment
Lung - NCT05671510
Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)
Open to Enrollment
Lung - NCT05546476
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study To Investigate The Efficacy, Safety and Tolerability of Ponsegromab in Patients with Cancer, Cachexia, and Elevated Concentrations of GDF-15, Followed By An Optional Open-Label Treatment Period
closed to enrollment
Prostate Cancer Trials:
Prostate - NCT06136650
A Study of MK-5684 Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Open to enrollment
Malignant Melanoma Trials:
No Active Trials
back to top ↑
Multiple Myeloma Trials:
Multiple Myeloma - NCT02952508
Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia (CLOVER-WaM)
Closed TO ENROLLMENT
Non-Hodgkin Lymphoma Trials:
Non-Hodgkin Lymphoma - NCT04384484
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS 5)
OPEN TO ENROLLMENT
Non-Hodgkin Lymphoma - NCT04938141
Medical Events of Interest and Health-Related Quality of Life in Chronic Lymphocytic Leukemia Patients Initiating Treatment With Bruton's Tyrosine Kinase Inhibitors Acalabrutinib or Ibrutinib
acive - closed TO ENROLLMENT at site
Hematologic Malignancies Trials:
Hematologic - NCT04384484
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS 5)
OPEN TO ENROLLMENT
Hematologic - NCT05490446
A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Double-blind, Randomized, Placebo-Controlled (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes
NEW- Open to enrollment
Hematologic - NCT06093672
Phase 3 Randomized, open-label, multicenter phase 3 study to assess the efficacy and safety of Givinostat versus Hydroxyurea in JAK2V617F-positive high-risk Polycythemia Vera (GIV-IN PV) patients
open to enrollment
Hematologic - NCT02952508
Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia (CLOVER-WaM)
Closed TO ENROLLMENT
Other Trials:
Other - NCT05366881
cfMeDIP-seq Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease (CAMPERR)
Open to enrollment
Other - NCT02952508
An Open-Label, Multicenter, Phase 2 study of CLR 131 in patients with Relapsed or Refractory Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients with Waldenstrom Macroglobulinema (CLOVER-WaM)
closed TO ENROLLMENT
Other - NCT04384484
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS 5)
OPEN TO ENROLLMENT
Other - NCT05546476
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study To Investigate The Efficacy, Safety and Tolerability of Ponsegromab in Patients with Cancer, Cachexia, and Elevated Concentrations of GDF-15, Followed By An Optional Open-Label Treatment Period